Association of Granulocyte Colony-Stimulating Factor Treatment with Risk of Brain Metastasis in Advanced Stage Breast Cancer
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms251910756 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Yun-Sheng Tai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, An-Nan Hospital, China Medical University, Tainan 709, Taiwan. Hauptthemen laut MEDLINE: Breast Neoplasms, Granulocyte Colony-Stimulating Factor, Brain Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: An-Nan Hospital, China Medical University.
Abstract (Originalsprache)
The routine use of granulocyte colony-stimulating factor (GCSF) is not recommended for the prevention or treatment of chemotherapy-induced neutropenia or febrile neutropenia because risks associated with certain types of cancers, distant organ metastases, and primary tumor growth cannot be excluded. We examined the association between GCSF use and the incidence of brain metastasis (BM), as well as BM-free survival (BMFS). This retrospective cohort study included 121 stage IV breast cancer patients without confirmed BM at the time of diagnosis and who received at least one course of systematic chemotherapy or target therapy at a tertiary teaching hospital between 1 January 2014 and 31 December 2022. The effect of GCSF use on BM was assessed with other confounding factors in Cox regression analyses. In this retrospective cohort, patients who received GCSF treatment had a significantly higher incidence of BM than those who did not (34.9% vs. 13.8%, p = 0.011). Univariate Cox regression analysis showed that GCSF use, menopause status, hormone treatment, HER2 treatment, cumulative dosage, dosage density, and neutropenia were independent risk factors for BMFS (p < 0.05). GCSF users had a higher risk of BM (adjusted HR: 2.538; 95% CI: 1.127–5.716, p = 0.025) than nonusers. BM risk was significantly associated with those with neutropenia (RR: 1.84, 95% CI: 1.21, 2.80) but not with those without neutropenia (RR: 0.59, 95% CI: 0.41–0.84, Interaction p-value < 0.05). The higher the dose density of GCSF, the higher the risk compared with those who do not use GCSF (p for trend < 0.01). These preliminary results suggest that GCSF is associated with BM in patients with stage IV breast cancer who did not have BM at initial diagnosis. Further comprehensively designed large-scale observational studies are needed to confirm our preliminary results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, An-Nan Hospital, China Medical University, Tainan 709, Taiwan.
- Department of Obstetrics and Gynecology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi 600, Taiwan.
- Department of Radiology, An-Nan Hospital, China Medical University, Tainan 709, Taiwan.
- Department of Radiation Oncology, An-Nan Hospital, China Medical University, Tainan 709, Taiwan.
- Department of Pharmacy, Kaohsiung Show Chwan Memorial Hospital, Kaohsiung 821, Taiwan.
ORCID-Profile: Agnes L F Chan
Förderung
- An-Nan Hospital, China Medical University
Zitieren
APA
Tai, Y. S., Leung, J. H., Wang, S. Y., Leung, H. W. C., & Chan, A. L. F. (2024). Association of Granulocyte Colony-Stimulating Factor Treatment with Risk of Brain Metastasis in Advanced Stage Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910756
Vancouver
Tai YS, Leung JH, Wang SY, Leung HWC, Chan ALF. Association of Granulocyte Colony-Stimulating Factor Treatment with Risk of Brain Metastasis in Advanced Stage Breast Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910756
BibTeX
@article{Tai2024,
author = {Tai, Yun-Sheng and Leung, John Hang and Wang, Shyh-Yau and Leung, Henry W C and Chan, Agnes L F},
title = {Association of Granulocyte Colony-Stimulating Factor Treatment with Risk of Brain Metastasis in Advanced Stage Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms251910756}
}
EUVIMED